Producing in France costs twice as much as in Romania. Mayoly accepted it for colchicine, but the real question is elsewhere: who will pay the bill? Yesterday, the French laboratory inaugurated in Auxerre a production chain for this drug against gout, classified strategic. The total investment reaches 3 million euros. Problem: at the current rate of reimbursement, the operation is not profitable. Negotiations are therefore beginning with the hea…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
Producing in France costs twice as much as in Romania. Mayoly accepted it for colchicine, but the real question is elsewhere: who will pay the bill? Yesterday, the French laboratory inaugurated in Auxerre a production chain for this drug against gout, classified strategic. The total investment reaches 3 million euros. Problem: at the current rate of reimbursement, the operation is not profitable. Negotiations are therefore beginning with the hea…